Prostate Cancer Screening With cPSA Test Would Reduce Biopsies – Study
This article was originally published in The Gray Sheet
Executive Summary
Complexed prostate specific antigen (cPSA) test adoption would reduce the number of unnecessary biopsies, according to a study presented May 27 at the American Urological Association meeting in Orlando
You may also be interested in...
USPSTF Drops Opposition To Prostate Screening, Remains Skeptical
The U.S. Preventive Services Task Force will no longer recommend against routine prostate cancer screening, but cautions that the benefits have not been fully demonstrated
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.